Tue, Sep 23, 2014, 8:48 AM EDT - U.S. Markets open in 42 mins.


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • nonfollower3 nonfollower3 Dec 7, 2012 9:49 AM Flag

    the other side of the coin - dilution

    As the number of shares and dilution increases, the share price will stabilize. instead of the wild swings in stock price we should see a nice steady surge higher as more income is reported.

    These finicky finance professionals have trouble assigning a value on a company without steady income. it's coming, but the impatience on the board is rising.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Dilution is a necessary evil with biotech. It's a costly high risk/reward business. IMGN becomes de-risked with TDM-1 approval and this machine will start to generate cash. Not many drugs make past phase 3, amny biotech failures. Ability to consistently raise money is sign of belief and confidence in IMGN ADC platform. My biggest concern is an acquisition before the instrinsic value is fully realized.

      Anyway, chart looks strong through this tax selling and fiscal cliff risk off trading environment.

      Looking forward to ASH this weekend and Oppenheimer next week.

      Sentiment: Strong Buy

10.91-0.44(-3.88%)Sep 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.